502LBA LBA Orals: Preliminary safety, pharmacokinetics, and antitumor activity of RMC-9805, an oral, RAS(ON) G12D-selective, tri-complex inhibitor in patients with KRAS G12D pancreatic ductal adenocarcinoma (PDAC) from a phase 1 study in advanced solid tumors
Publication
, Conference
Hong, DS; Papadopoulos, K; Kim, DW; Parikh, A; Barve, M; Powderly, J; Starodub, A; Strickler, J; Li, BT; Oberstein, P; Yu, W; Bitman, B ...
Published in: European Journal of Cancer
October 2024
Duke Scholars
Published In
European Journal of Cancer
DOI
ISSN
0959-8049
Publication Date
October 2024
Volume
211
Start / End Page
114980 / 114980
Publisher
Elsevier BV
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1117 Public Health and Health Services
- 1112 Oncology and Carcinogenesis
Citation
APA
Chicago
ICMJE
MLA
NLM
Hong, D. S., Papadopoulos, K., Kim, D. W., Parikh, A., Barve, M., Powderly, J., … Spira, A. (2024). 502LBA LBA Orals: Preliminary safety, pharmacokinetics, and antitumor activity of RMC-9805, an oral, RAS(ON) G12D-selective, tri-complex inhibitor in patients with KRAS G12D pancreatic ductal adenocarcinoma (PDAC) from a phase 1 study in advanced solid tumors. In European Journal of Cancer (Vol. 211, pp. 114980–114980). Elsevier BV. https://doi.org/10.1016/j.ejca.2024.114980
Hong, D. S., K. Papadopoulos, D. W. Kim, A. Parikh, M. Barve, J. Powderly, A. Starodub, et al. “502LBA LBA Orals: Preliminary safety, pharmacokinetics, and antitumor activity of RMC-9805, an oral, RAS(ON) G12D-selective, tri-complex inhibitor in patients with KRAS G12D pancreatic ductal adenocarcinoma (PDAC) from a phase 1 study in advanced solid tumors.” In European Journal of Cancer, 211:114980–114980. Elsevier BV, 2024. https://doi.org/10.1016/j.ejca.2024.114980.
Hong DS, Papadopoulos K, Kim DW, Parikh A, Barve M, Powderly J, et al. 502LBA LBA Orals: Preliminary safety, pharmacokinetics, and antitumor activity of RMC-9805, an oral, RAS(ON) G12D-selective, tri-complex inhibitor in patients with KRAS G12D pancreatic ductal adenocarcinoma (PDAC) from a phase 1 study in advanced solid tumors. In: European Journal of Cancer. Elsevier BV; 2024. p. 114980–114980.
Hong, D. S., et al. “502LBA LBA Orals: Preliminary safety, pharmacokinetics, and antitumor activity of RMC-9805, an oral, RAS(ON) G12D-selective, tri-complex inhibitor in patients with KRAS G12D pancreatic ductal adenocarcinoma (PDAC) from a phase 1 study in advanced solid tumors.” European Journal of Cancer, vol. 211, Elsevier BV, 2024, pp. 114980–114980. Crossref, doi:10.1016/j.ejca.2024.114980.
Hong DS, Papadopoulos K, Kim DW, Parikh A, Barve M, Powderly J, Starodub A, Strickler J, Li BT, Oberstein P, Yu W, Bitman B, Lally S, Lin W, Sohoni S, Spira A. 502LBA LBA Orals: Preliminary safety, pharmacokinetics, and antitumor activity of RMC-9805, an oral, RAS(ON) G12D-selective, tri-complex inhibitor in patients with KRAS G12D pancreatic ductal adenocarcinoma (PDAC) from a phase 1 study in advanced solid tumors. European Journal of Cancer. Elsevier BV; 2024. p. 114980–114980.
Published In
European Journal of Cancer
DOI
ISSN
0959-8049
Publication Date
October 2024
Volume
211
Start / End Page
114980 / 114980
Publisher
Elsevier BV
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1117 Public Health and Health Services
- 1112 Oncology and Carcinogenesis